Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT07547228Phase 2Recruiting
- Sponsor
- Intra-ImmuSG
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of PRL3-zumab in neovascular age-related macular degeneration (NVAMD), sponsored by Intra-ImmuSG. Started Oct 2025; status: recruiting.
02
Drugs
PRL3-zumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07547228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547228.